Login to Your Account


PARP INHIBITOR APPROVED FOR MAINTENANCE THERAPY

Even as Tesaro Inc. prepares to launch newly approved Zejula late next month in ovarian cancer, the company already is setting sights on an expanded clinical development program for the PARP inhibitor, which is not restricted to patients with BRCA mutations.

more »


Our Habitat for All Things Science
Specific lead identified in the fight against TB

Novel analogues of a class of antibacterial compounds isolated from soil bacteria could lead to the development of urgently needed new treatments for tuberculosis (TB), according to the findings of a study led by Australian researchers at the University of Sydney.

Worldwide, TB causes more deaths than any other infectious disease including HIV/AIDs. According to the WHO, there were an estimated 10.4 million new cases of TB and 1.8 million deaths in 2015, with 60 percent of all new cases occurring in Asia.

READ MORE »

Opinion


Partners in Focus